# New England Journal of Medicine

Source: https://nuclide.cc/journals/nejm/  
Nuclide record `nejm` (Journal). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)"; commercial use needs a licence.

## TL;DR

NEJM is the most influential medical journal. When a cancer drug trial changes how patients are treated, the paper is usually here, often published the same day it is presented at ASCO, ESMO or ASH.

## Summary

Weekly general-medicine journal with the highest bar for randomised evidence and the largest share of practice-changing oncology phase 3 trials (IRIS imatinib, KEYNOTE-189, DESTINY-Breast04, CheckMate 067, ZUMA-1 and dozens more in this corpus). Editorials and correspondence often carry the critical reading of a trial. Paywalled, with abstracts free and many trial papers free six months after publication; requires a data-sharing statement for clinical trials under ICMJE rules.

## Fields

- Kind: Journal
- Last checked: 2026-09-09
- Also known as: NEJM; N Engl J Med; src-nejm
- Publisher: NEJM Group / Massachusetts Medical Society
- Scope: general medicine
- Access: subscription

## Notes

- Holds: The practice-changing phase 3 trials, most published simultaneously with ASCO, ESMO and ASH presentations. Access: Paywalled; abstracts free; many trial papers free after 6 months.

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/The_New_England_Journal_of_Medicine
- Hematology/Oncology specialty page: https://www.nejm.org/browse/specialty/hematology-oncology

## Connected records

- key papers: [ALSYMPCA: alpha emitter radium-223 and survival in metastatic prostate cancer with bone metastases](https://nuclide.cc/key-papers/paper-alsympca-radium-223-nejm-2013/), [CABINET (Alliance A021602): cabozantinib for advanced neuroendocrine tumours](https://nuclide.cc/key-papers/paper-cabinet-cabozantinib-nejm-2024/), [CLARINET: lanreotide in metastatic enteropancreatic neuroendocrine tumours](https://nuclide.cc/key-papers/paper-clarinet-lanreotide-nejm-2014/), [NETTER-1: 177Lu-Dotatate for midgut neuroendocrine tumours progressing on octreotide](https://nuclide.cc/key-papers/paper-netter-1-nejm-2017/), [RATHL: adapted treatment guided by interim PET-CT in advanced Hodgkin lymphoma](https://nuclide.cc/key-papers/paper-rathl-interim-pet-adapted-abvd-advanced-hodgkin-nejm-2016/), [VISION: lutetium-177 PSMA-617 radioligand therapy extends survival in advanced prostate cancer](https://nuclide.cc/key-papers/paper-vision-nejm-2021/)

---
JSON: https://nuclide.cc/api/v1/entities/nejm.json